The FDA has shown its’ hand. The Plausible Mechanism Framework and new NGS safety guidance signal one thing clearly: regulators want genome editing therapies to reach patients. Biopharma is also pushing back with a surge of novel genome editing assets deployed in the last 2 years, targeting rare and prevalent diseases with scarce treatment options.

But intent and support alone won’t get these therapies to patients. Developmental, manufacturing, and regulatory challenges still stand between the lab and the patients waiting.

That’s why the 7th Genome Editing Therapeutics Summit is returning to Boston this September, as the only industry-focused meeting dedicated to applying breakthrough genome editing tools directly to the therapeutic setting.

Join R&D, preclinical, translational, regulatory, and c-suite leaders to answer one question: how do we maximize the application of genome editing therapies to patients who need them most?

Don’t miss out on insights from AbbVie, Bristol Myers Squibb, Intellia Therapeutics, Beam Therapeutics, Sanofi, and many more on how genome editing can move from a promising therapy to an essential one for patients facing the most genetically complex diseases.  

What’s New in 2026?

In 2026, companies are doubling down on translating cutting-edge genome editing technologies into clinically viable therapies. With the FDA’s new mechanism pathway reshaping strategy, the decisions made now will determine which assets reach patients.

At this year’s summit you will:

• Delve into extrahepatic delivery strategies to widen your technology across multiple disease indications

• Learn from clinical companies building robust IND packages to fast-track development

• Evaluate immunogenicity and off-targeting case studies to sharpen your therapy’s safety profile

Explore the Brand-New Agenda to Discover:

• 3 days of content to find the sessions your program needs most

• 50:50 clinical & preclinical speakers to find genome editing talks relevant to your development stage

• 80% Directors, VPs & C-suite to benchmark your genome editing strategy against the right decision-makers

• 64% in vivo & 36% ex vivo agenda to fit your route of delivery

• 2 brand-new workshops

View the full program here to see the 18+ speaker faculty and full session details: https://ter.li/sda9n7qy